Tudor Investment Corp Et Al buys $50,262,750 stake in C R Bard Inc (BCR)

C R Bard Inc (BCR) : Tudor Investment Corp Et Al scooped up 70,923 additional shares in C R Bard Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 225,900 shares of C R Bard Inc which is valued at $50,262,750.C R Bard Inc makes up approximately 1.92% of Tudor Investment Corp Et Al’s portfolio.

Other Hedge Funds, Including , Gotham Asset Management reduced its stake in BCR by selling 145,295 shares or 96.3% in the most recent quarter. The Hedge Fund company now holds 5,582 shares of BCR which is valued at $1,241,995. C R Bard Inc makes up approx 0.01% of Gotham Asset Management’s portfolio.Pinebridge Investments reduced its stake in BCR by selling 37,297 shares or 90.01% in the most recent quarter. The Hedge Fund company now holds 4,140 shares of BCR which is valued at $921,150. C R Bard Inc makes up approx 0.05% of Pinebridge Investments’s portfolio.Thompson Davis boosted its stake in BCR in the latest quarter, The investment management firm added 830 additional shares and now holds a total of 907 shares of C R Bard Inc which is valued at $200,864. C R Bard Inc makes up approx 0.31% of Thompson Davis’s portfolio.

C R Bard Inc opened for trading at $220.91 and hit $221.72 on the upside on Thursday, eventually ending the session at $221.5, with a gain of 0.30% or 0.66 points. The heightened volatility saw the trading volume jump to 3,45,697 shares. Company has a market cap of $16,270 M.

On the company’s financial health, C R Bard Inc reported $2.34 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $2.17. The company had revenue of $873.50 million for the quarter, compared to analysts expectations of $847.53 million. The company’s revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.10 EPS.

Many Wall Street Analysts have commented on C R Bard Inc. Company shares were Reiterated by Deutsche Bank on Jul 27, 2016 to “Hold”, Firm has raised the Price Target to $ 240 from a previous price target of $234 .Company shares were Reiterated by Barclays on Jul 27, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 235 from a previous price target of $224 .C R Bard Inc was Downgraded by BofA/Merrill to ” Neutral” on Jul 8, 2016.

C. R. Bard Inc. (Bard) and its subsidiaries are engaged in the design manufacture packaging distribution and sale of medical surgical diagnostic and patient care devices. . The Company reports its sales in four major product group categories: vascular urology oncology and surgical specialty. The Company also has a product group of other products. The Company’s vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and heart arrhythmias. Its urology products include basic urology drainage products fecal and urinary continence products urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and other soft tissue repairs in addition to hemostats and surgical sealants.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *